EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

ABSTRACT:

Background

Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial.

Methods

Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cance

SUBMITTER: Cheng H 

PROVIDER: S-EPMC4453859 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature